Impact of Adjuvant Medical Therapies on Surgical Outcomes in Idiopathic Subglottic Stenosis
Authors:
- Matthew R. HoffmanMHMatthew R. Hoffman
- Ankita PatroAPAnkita Patro
- Alexander GelbardAGAlexander Gelbard
- North American Airway CollaborativeNCNorth American Airway Collaborative
- 12 June 2021
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 131 (12) , E2880-E2886
Abstract
Objectives/Hypothesis: Adjuvant medications including proton pump inhibitors (PPI), antibiotics (trimethoprim/sulfamethoxazole [TMP‐SMX]), and inhaled corticosteroids (ICS) may be prescribed for patients with idiopathic subglottic stenosis (iSGS). We describe medication use with endoscopic dilation (ED) or endoscopic resection with medical treatment (ERMT) and evaluate impact on outcomes.Study Design: International, prospective, 3‐year multicenter cohort study of 810 patients with untreated, newly diagnosed, or previously treated iSGS.Methods: Post hoc secondary analysis of prospectively collected North American Airway Collaborative data on outcomes linked with adjuvant medication utilization. Primary outcome was time to recurrent operation, evaluated using Kaplan–Meier curves and Cox regression analysis. Secondary outcomes of change in peak expiratory flow (PEF) and clinical chronic obstructive pulmonary disease questionnaire (CCQ) score over 12 months were compared.Results: Sixty‐one of 129 patients undergoing ED received PPI (47%), and 10/143 patients undergoing ED received ICS (7%). TMP‐SMX was used by 87/115 patients (76%) undergoing EMRT. PPI use in the ED group did not affect time to recurrence (hazard ratio [HR] = 1.00, 95% confidence interval [CI]: 0.53–1.88; P = .99) or 12‐month change in PEF (L/min) (median [interquartile range], 12.0 [10.7–12.2] vs. 8.7 [−5.1 to 24.9]; P = .59), but was associated with 12‐month change in CCQ (−0.05 [−0.97 to 0.75] vs. −0.50 [−1.60 to 0.20]; P = .04). ICS did not affect outcome measures. TMP‐SMX use in ERMT did not affect time to recurrence (HR = 0.842, 95% CI: 0.2345–3.023; P = .79), PEF at 12 months (75 [68–89] vs. 81 [68–89]; P = .92), or 12‐month change in CCQ (0.20 [−1.05 to 0.47] vs. −0.30 [−1.00 to 0.10]; P = .45).Conclusion: There is no standard practice for prescribing adjuvant medications. These data do not support that adjuvant medications prolong time to recurrence or increase PEF. Patients with iSGS and gastroesophageal reflux disease may experience some symptom benefit with PPI.Level of Evidence: 3 Laryngoscope, 131:E2880–E2886, 2021Keywords
Funding Information
- National Cancer Institute (R01CA251566‐01)
- National Heart, Lung, and Blood Institute (R01HL146401‐01)
This publication has 26 references indexed in Scilit:
- Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosisThe Laryngoscope, 2015
- Causes and consequences of adult laryngotracheal stenosisThe Laryngoscope, 2014
- The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important differenceThorax, 2013
- Idiopathic subglottic stenosis: An evolving therapeutic algorithmThe Laryngoscope, 2013
- Treatment for adult idiopathic and Wegener-associated subglottic stenosis2012
- Evidence of extraesophageal reflux in idiopathic subglottic stenosisThe Laryngoscope, 2011
- Validation of the Clinical COPD Questionnaire as a psychophysical outcome measure in adult laryngotracheal stenosisClinical Otolaryngology, 2009
- Idiopathic Tracheal StenosisAmerican Journal of Surgical Pathology, 2008
- Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's GranulomatosisNew England Journal of Medicine, 1996
- Gastroesophageal Reflux Disease as a Likely Cause of “Idiopathic” Subglottic StenosisAnnals of Otology, Rhinology & Laryngology, 1994